Past Events
JANSSEN LABS | A capital efficient, flexible model for companies pursuing healthcare innovations
January 9, 2012 | San Francisco | 111 Minna Gallery
Accelerate Your Discovery: J.P. Morgan Networking Reception (Invitation only)
January 16, 2012 | Janssen Labs | San Diego
Janssen Labs Grand Opening Evening Reception (Invitation only)
June 28, 2012 | Janssen Research & Development LLC
3210 Merryfield Row
San Diego, CA 92121
Investors with Current Funds: Who is Catalyzing Life Science Start-ups?: Prescience International invites you to join four of the nation’s leading venture capitalists – all with current funds - for an in-depth look into the capital process and current trends in life science financing. This powerhouse panel will discuss such topics as building a company from the ground up, new models for venture-backed businesses and what warning signs make investors turn and run. This candid presentation will bring together some of the most experienced venture capitalists from both Silicon Valley and San Diego for an interactive dialogue discussing where new opportunities for investment lie, and how to best position your company to attract such funding.
Speakers:
Rowan Chapman | Partner, Mohr Davidow Ventures
David Coats | Managing Director, Correlation Ventures
Anand Mehra | Partner, Sofinnova Ventures
Pratik Shah| Parner, Thomas, McNerney & Partners
Diego Miralles| Head, Janssen Research & Development West Coast Research Center and Janssen Healthcare Innovation (moderator)
August 23, 2012 | Janssen Research & Development LLC
3210 Merryfield Row
San Diego, CA 92121
Meet with The National Cancer Institute: Is your company looking for funding? Join us for a presentation by leadership from NCI's Small Business Innovation Research (SBIR) program, and apply to meet one-on-one with the speakers for a private discussion on the funding opportunities currently available for entrepreneurs.
Speakers:
Michael Weingarten | Director, SBIR Development Center, National Cancer Institute
Andrew Kurtz | Program Director, SBIR Development Center, National Cancer Institute
September 13, 2012 | Janssen Research & Development LLC
3210 Merryfield Row
San Diego, CA 92121
Open Innovation: How BIG Pharma is Shaking Things Up: In recent years, the pharmaceutical industry has undeniably become more receptive to partnerships, more creative when thinking of ways to engage start-ups and more welcoming to joint ventures for the advancement of R&D. Join leaders from four of the industry's largest companies for an in-depth and candid discussion on how these innovation models are expected to do much more than simply 'reinvent the wheel.'
Panelists:
Christopher Haskell | Head, US Science Hub, Bayer Healthcare Pharmaceuticals
Diego Miralles | Head, Janssen Research & Development West Coast Research Center and Janssen Healthcare Innovation
Neela Patel | Director, Global External Research-West Coast, Abbott
Bhasker Shetty | Vice President, Pfizer Worldwide R&D
Michael Penn | Vice President of Strategy, Gladstone Institute - Moderator (TBC)
November 15, 2012 | Janssen Research & Development LLC
3210 Merryfield Row
San Diego, CA 92121
The Road to the Biologic IND: Prescience International invites you for an in-depth look into the process of filing a biologic Investigational New Drug (IND) application and the procedures necessary for advancing your company’s early-stage drug development program. Whether your goal is to develop a pipeline through commercial launch, or partner as early as possible, submitting an IND is a critical early milestone for every biotech company. With big Pharma and VC firms competing for the most promising compounds, startups are expected to demonstrate a solid plan for achieving IND acceptance. Join us for a series of presentations, hosted by Laureate Biopharmaceutical Services, exploring the basic requirements and considerations that you need to be aware of when planning for a successful biologic IND submission. Presentations will highlight the following: • Key components of the Chemistry/Manufacturing/Controls • Expression, Purification, Analytics, Formulation, Fill/Finish • Preclinical study design, species selection, material requirements and timelines • Regulatory requirements, strategies to minimize costs and timelines while balancing risk
Speakers:
Michiel Ultee | Chief Scientific Officer, Laureate BioPharmaceutical Services
Robert Burford | VP Regulatory Affairs, Laureate BioPharmaceutical Services
Brian Rogers | Founding Partner & VP of Toxicology, Pacific BioDevelopment
November 29, 2012 | Janssen Research & Development LLC
3210 Merryfield Row
San Diego, CA 92121
Bench to Boardroom Lecture: Featuring Jennerex Biotherapeutics: Join us for lunch on November 29 to hear from David Kirn, a global leader in the clinical research and development of oncolytic viruses for cancer as he reveals the success story behind Jennerex Biotherapeutics. One of the Bay Area’s most promising clinical-stage biotherapeutics companies, Jennerex’s lead product is currently in a Phase 2b clinical trial for hepatocellular carcinoma and Phase 1/2 clinical development for colorectal cancer. Whether you are in the oncology field or simply interested in networking with the industry’s top execs, join us as Kirn shares insight into the science on which Jennerex is based, shares tips for founding a successful start-up and weighs in on his vision for the future direction of the life science field.
Speakers:
David Kirn | President, Founder and Chief Medical Officer, Jennerex Biotherapeutics
December 4, 2012 | Janssen Research & Development LLC
3210 Merryfield Row
San Diego, CA 92121
Meet with…Thomas, McNerney & Partners: Thomas, McNerney & Partners is a national venture firm investing in life science and medical technology companies at all stages of development. Three members of the firm’s team will be in attendance on December 4 to give an overview presentation on their key areas of interest, background on their current portfolio and best practices when starting down the road of venture capital investment. Following the presentation, don’t miss this opportunity to introduce yourself to the firm during the event’s networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Thomas, McNerney will provide a forum to further discuss your company with the firm’s team leaders.
Speakers:
Pratik Shah | Partner, Thomas, McNerney & Partners
Jason Brown | Principal, Thomas, McNerney & Partners
Justin Chakma | Analyst, Thomas, McNerney & Partners
December 12, 2012 | Janssen Research & Development LLC
3210 Merryfield Row
San Diego, CA 92121
Funding in Biotech: What Lies Ahead for 2013?: Some of the most successful CEOs and company founders in the industry from both the Bay Area and San Diego will come together for a candid discussion on the future of life science investing in the coming year. These premier speakers will share insights into where they have secured funding from in the past, the pitfalls to be avoided when attempting to raise capital, and what types of partnerships they would recommend in order to spur growth. These seasoned entrepreneurs have experienced it all from bootstrapping your initial R&D to raising millions in multiple ventures rounds, from taking companies public to being acquired by big pharma. Their track records in building innovative and successful businesses speak for themselves – so join us for what will be not only be a riveting and thought-provoking panel discussion, but a great chance to ring in the new year with the life science industry’s top execs.
Speakers:
John Diekman | Founder & Managing Partner, 5AM Ventures (moderator)
Faheem Hasnain | President & CEO, Receptos, Inc.
Peter Hirth | CEO, Plexxikon
Guy Miller | Chairman & CEO, Edison Pharmaceuticals
Susan Molineaux | President & CEO, Calithera Biosciences, Inc.
Troy Wilson | President & CEO, Wellspring Biosciences
February 5, 2013 | Janssen Research & Development LLC
3210 Merryfield Row
San Diego, CA 92121
Janssen Labs Open House Tours: Have you heard about Janssen Labs, the new life science innovation center created by Janssen Research & Development, but not yet seen the space for yourself? Join us on February 5 for a guided tour of the 30,000 square foot research facility and a chance to learn more about the project first-hand. Created to provide an efficient way for companies to discover and develop solutions to healthcare challenges, Janssen Labs offers modular and scalable lab units, designed to grow with companies, and access to core research facilities with specialized equipment and administrative areas. Janssen Labs has already welcomed 15 emerging life sciences companies since its Grand Opening in January 2012. The facility can accommodate a maximum of 18 to 20 companies, and the application process will continue throughout 2013. Come see for yourself how innovation is thriving at Janssen Labs.
